Activities of ceftobiprole, a novel broad-spectrum cephalosporin, against Haemophilus influenzae and Moraxella catarrhalis.
about
Ceftobiprole for the treatment of pneumonia: a European perspectiveCeftobiprole medocaril in the treatment of hospital-acquired pneumoniaResistance and the management of complicated skin and skin structure infections: the role of ceftobiprole.Ceftobiprole activity against over 60,000 clinical bacterial pathogens isolated in Europe, Turkey, and Israel from 2005 to 2010.Ceftobiprole medocaril: a review of its use in patients with hospital- or community-acquired pneumonia.Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae.Emerging agents to combat complicated and resistant infections: focus on ceftobiproleResults of a double-blind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by gram-positive bacteria.Genotypic Characterization of Methicillin-Resistant Staphylococcus aureus Recovered at Baseline from Phase 3 Pneumonia Clinical Trials for Ceftobiprole.Investigational treatments for postoperative surgical site infections.Ceftobiprole: an extended-spectrum anti-methicillin-resistant Staphylococcus aureus cephalosporin.Ceftobiprole: a new broad spectrum cephalosporin.Ceftobiprole: a new cephalosporin for the treatment of skin and skin structure infections.β-lactams against emerging 'superbugs': progress and pitfalls.Activities of ceftobiprole, linezolid, vancomycin, and daptomycin against community-associated and hospital-associated methicillin-resistant Staphylococcus aureus.In vitro capability of faropenem to select for resistant mutants of Streptococcus pneumoniae and Haemophilus influenzae.Multistep resistance development studies of ceftaroline in gram-positive and -negative bacteria.Time-kill and synergism studies of ceftobiprole against Enterococcus faecalis, including beta-lactamase-producing and vancomycin-resistant isolates
P2860
Q26796463-7378C1C0-DCD1-41CC-BE8B-494B05EBEBE1Q28085517-6566B6DC-5CC7-47DB-9294-075D94B33FF8Q34187667-370C51A8-0F28-4938-8FDE-EC762B5F34C0Q34417616-57D67906-8D03-4A28-86E5-AE2B800C60B6Q34433342-C21172EF-7E8C-4232-B4B5-38FEEE9D758EQ34624359-61789CA0-2E3C-444A-AA03-FF8A9EBEF95FQ35026567-4172208B-5B29-41A8-B42D-E7AC8B991AE1Q36422630-E24859C2-8089-48FC-A81E-4BB7DB57E242Q36489501-6BFF156E-398A-4FB0-A77F-79D6BF26E9B4Q36715742-13A4CE1A-A84C-4214-8E18-9CC33DFE5B23Q37162872-D816C029-9186-465A-A85B-5E8D7C2FA05BQ37519733-17505931-18B4-4963-ABAB-C9F17FD1BDD4Q37593094-05EE44EC-E4E8-4D8A-B4B3-58DF1F36E3D0Q38177344-2F46BB0F-9812-474E-83F0-78A3D2E348D4Q41336401-CC443151-E49F-48DE-80AF-B3F24A50A83CQ41838198-43C67AF9-F98E-4AE0-9A6C-12A8AE0F8791Q42111061-495CD1FC-C021-43D1-826A-9CFEC562EB1FQ42747697-636E5266-085C-4FA6-A5B9-2E31AE02A740
P2860
Activities of ceftobiprole, a novel broad-spectrum cephalosporin, against Haemophilus influenzae and Moraxella catarrhalis.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Activities of ceftobiprole, a ...... zae and Moraxella catarrhalis.
@en
type
label
Activities of ceftobiprole, a ...... zae and Moraxella catarrhalis.
@en
prefLabel
Activities of ceftobiprole, a ...... zae and Moraxella catarrhalis.
@en
P2093
P2860
P356
P1476
Activities of ceftobiprole, a ...... zae and Moraxella catarrhalis.
@en
P2093
Catherine Clark
Gengrong Lin
Kathy Smith
Lois Ednie
Peter C Appelbaum
Stuart Shapiro
Tatiana Bogdanovich
P2860
P304
P356
10.1128/AAC.00044-06
P407
P577
2006-06-01T00:00:00Z